{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:50:42Z","timestamp":1792270242494,"version":"4.4.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec id=\"ab-ioi250036-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Congress established the US Food and Drug Administration (FDA) Breakthrough Devices Program (BDP) in 2016 to promote technological innovation and facilitate patient access. However, the clinical and regulatory characteristics of FDA-designated breakthrough devices have not been assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250036-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize technological novelty, FDA review times, and premarket and postmarket evidence requirements for therapeutic breakthrough-designated devices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250036-6\">\n                    <jats:title>Design and Setting<\/jats:title>\n                    <jats:p>This cross-sectional study analyzed publicly available FDA data for all therapeutic breakthrough-designated devices receiving FDA authorization between January 1, 2016, and September 30, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250036-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>(1) Device novelty (first of a kind and first commercialized launch); (2) FDA premarket review times (compared with Medical Device User Fee Authorization [MDUFA] goals); (3) premarket pivotal study characteristics; and (4) postmarket regulatory experience (FDA-required studies and recalls).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250036-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between January 1, 2016, and September 30, 2024, the FDA granted breakthrough designations to 1041 devices, 127 of which have been authorized (12.2%), including 75 therapeutic devices (59.1%). Thirty-four of 75 therapeutic devices (45.3%) were classified as high-risk; within this subgroup, 23 were first of a kind (67.6%) and 14 were first commercialized in the US (41.4%). The mean (SD) FDA review time was 225.8 (107.6) days for all 75 devices and 243.3 (98.4) days for the 34 high-risk devices. MDUFA goals for FDA review times applied to 30 high-risk devices, of which 22 (73.3%) were reviewed before statutory target timeframes. Most therapeutic devices (89.3% [67 of 75]) underwent premarket clinical testing, totaling 75 pivotal studies evaluating 81 primary effectiveness end points. Forty end points (49.4%) incorporated surrogate measures of effectiveness, and 15 (18.5%) lacked statistical testing. End points had short follow-up durations (median, 6 months [IQR, 3.8-12 months] for implantable devices). The FDA required 46 postmarket studies for 30 breakthrough-designated devices (40.0%); 19 studies reported delays (41.3%). The mean (SD) US market life to date was 2.4 (1.9) years, during which 12.0% of devices (9 of 75) were recalled, including 1 class I (1.3%) (ie, highest severity) recall.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250036-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This study found that most therapeutic breakthrough\u2013designated devices are novel and reviewed by the FDA before statutory target timeframes. However, uncertainty about benefits and risks for some devices raises questions whether BDP is consistently fulfilling program objectives to improve public health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.2235","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:00:40Z","timestamp":1751281240000},"page":"996","source":"Crossref","is-referenced-by-count":13,"title":["FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program"],"prefix":"10.1001","volume":"185","author":[{"given":"Kushal T.","family":"Kadakia","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket S.","family":"Dhruva","sequence":"additional","affiliation":[{"name":"Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, California"},{"name":"Section of Cardiology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University College of Medicine, Columbus"},{"name":"The Center for the Advancement of Team Science, Analytics, and Systems Thinking in Health Services and Implementation Science Research (CATALYST), Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Rathi","sequence":"additional","affiliation":[{"name":"The Center for the Advancement of Team Science, Analytics, and Systems Thinking in Health Services and Implementation Science Research (CATALYST), Columbus, Ohio"},{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"ioi250036r1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jama.2021.11171","article-title":"FDA regulation and approval of medical devices: 1976-2020.","volume":"326","author":"Darrow","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"ioi250036r2","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.7326\/ANNALS-24-01840","article-title":"Getting the balance of safety and speed of medical device approval right.","volume":"177","author":"Emanuel","year":"2024","journal-title":"Ann Intern Med"},{"issue":"9","key":"ioi250036r5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1056\/NEJMsr1610625","article-title":"Conflicts of interest for patient-advocacy organizations.","volume":"376","author":"McCoy","year":"2017","journal-title":"N Engl J Med"},{"key":"ioi250036r7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jpubeco.2016.11.010","article-title":"Innovation under regulatory uncertainty: evidence from medical technology.","volume":"145","author":"Stern","year":"2017","journal-title":"J Public Econ"},{"issue":"12","key":"ioi250036r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49298","article-title":"Market of first launch for high-risk therapeutic medical devices.","volume":"7","author":"Kadakia","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"ioi250036r12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41587-020-0636-7","article-title":"Early experience with the FDA\u2019s Breakthrough Devices program.","volume":"38","author":"Johnston","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"6","key":"ioi250036r15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1001\/jama.2015.8761","article-title":"Characteristics of clinical studies conducted over the total product life cycle of high-risk therapeutic medical devices receiving FDA premarket approval in 2010 and 2011.","volume":"314","author":"Rathi","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"ioi250036r16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/jamapediatrics.2022.4131","article-title":"High-risk therapeutic devices approved by the US Food and Drug Administration for use in children and adolescents from 2016 to 2021.","volume":"177","author":"Pathak","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"1","key":"ioi250036r17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjsit-2022-000152","article-title":"Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018.","volume":"5","author":"Rathi","year":"2023","journal-title":"BMJ Surg Interv Health Technol"},{"issue":"3","key":"ioi250036r19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1056\/NEJMp2204947","article-title":"Medical device user fee reauthorization\u2014back to the basics or looking ahead?","volume":"387","author":"Rathi","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"ioi250036r21","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1001\/jama.2009.1899","article-title":"Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.","volume":"302","author":"Dhruva","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"ioi250036r22","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.7326\/ANNALS-24-00724","article-title":"Class I recalls of cardiovascular devices between 2013 and 2022: a cross-sectional analysis.","volume":"177","author":"See","year":"2024","journal-title":"Ann Intern Med"},{"issue":"7","key":"ioi250036r23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"issue":"19","key":"ioi250036r24","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1001\/jama.2024.4175","article-title":"Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments.","volume":"331","author":"Wallach","year":"2024","journal-title":"JAMA"},{"issue":"12","key":"ioi250036r25","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamacardio.2023.3819","article-title":"Aligning US agency policies for cardiovascular devices through the breakthrough devices program.","volume":"8","author":"Moneer","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"7","key":"ioi250036r26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jchf.2018.03.017","article-title":"Validation of exercise capacity as a surrogate endpoint in exercise based rehabilitation for heart failure: a meta-analysis of randomized controlled trials.","volume":"6","author":"Ciani","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"9","key":"ioi250036r27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.7326\/0003-4819-149-9-200811040-00004","article-title":"Composite outcomes in cardiovascular research: a survey of randomized trials.","volume":"149","author":"Lim","year":"2008","journal-title":"Ann Intern Med"},{"issue":"10","key":"ioi250036r28","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamainternmed.2021.3042","article-title":"Assessment of FDA approval for new high-risk therapeutic devices not meeting pivotal study primary end points, 2016-2020.","volume":"181","author":"Johnston","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"2","key":"ioi250036r38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117235","article-title":"Characteristics of pivotal trials and FDA review of innovative devices.","volume":"10","author":"Rising","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"ioi250036r40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMp1211581","article-title":"The 510(k) ancestry of a metal-on-metal hip implant.","volume":"368","author":"Ardaugh","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"ioi250036r42","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jamainternmed.2015.5355","article-title":"A randomized trial testing US Food and Drug Administration \u201cbreakthrough\u201d language.","volume":"175","author":"Krishnamurti","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"14","key":"ioi250036r43","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1001\/jama.2015.16984","article-title":"Physicians\u2019 knowledge about FDA approval standards and perceptions of the \u201cbreakthrough therapy\u201d designation.","volume":"315","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"ioi250036r44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1377\/hlthaff.2023.00466","article-title":"Physicians\u2019 perspectives on FDA regulation of drugs and medical devices: a national survey.","volume":"43","author":"Dhruva","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"16","key":"ioi250036r45","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The on- and off-ramps of oncology accelerated approval.","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi250036r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7274","article-title":"Risk of recall among medical devices undergoing US Food and Drug Administration 510(k) clearance and premarket approval, 2008-2017.","volume":"4","author":"Dubin","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ioi250036r3","unstructured":"PricewaterhouseCoopers. Medical technology innovation scorecard: the race for global leadership. January 2011. Accessed December 9, 2024. https:\/\/www.pwc.com\/il\/en\/pharmaceuticals\/assets\/innovation-scorecard.pdf."},{"key":"ioi250036r4","unstructured":"Gottlieb? S. How the FDA could cost you your life. The Wall Street Journal. October 3, 2011. Accessed December 9, 2024. https:\/\/www.wsj.com\/articles\/SB10001424052970204831304576597200095602270"},{"key":"ioi250036r6","unstructured":"EY. Pulse of the industry: medical technology report 2023. https:\/\/www.advamed.org\/wp-content\/uploads\/2023\/10\/ey-pulse-of-the-industry-medical-technology-report-2023.pdf. 2023. Accessed December 9, 2024."},{"key":"ioi250036r9","unstructured":"The Institute of Medicine. Medical devices and the public\u2019s health: the 510(k) clearance process at 35 years. 2011. Accessed December 9, 2024. https:\/\/nap.nationalacademies.org\/catalog\/13150\/medical-devices-and-the-publics-health-the-fda-510k-clearance."},{"key":"ioi250036r10","unstructured":"U.S. Food and Drug Administration. Breakthrough devices program. September 15, 2023. Accessed December 9, 2024. https:\/\/www.fda.gov\/media\/162413\/download."},{"key":"ioi250036r11","unstructured":"Palmer? K, Aguilar? M. FDA\u2019s breakthrough device program, meant to benefit patients, is delivering the biggest gains for companies. April 18, 2022. Accessed December 9, 2024. https:\/\/www.statnews.com\/2022\/04\/18\/fda-breakthrough-device-designation-investigation\/."},{"key":"ioi250036r13","unstructured":"U.S. Food and Drug Administration. Breakthrough devices program. March 21, 2024. Accessed December 9, 2024. https:\/\/www.fda.gov\/medical-devices\/how-study-and-market-your-device\/breakthrough-devices-program."},{"key":"ioi250036r14","unstructured":"U.S. Food and Drug Administration. Devices@FDA. October 28, 2024. December 9, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/devicesatfda\/index.cfm."},{"key":"ioi250036r18","unstructured":"U.S. Food and Drug Administration. Medical device user fee amendments. October 3, 2024. November 2, 2024. https:\/\/www.fda.gov\/industry\/fda-user-fee-programs\/medical-device-user-fee-amendments-mdufa."},{"key":"ioi250036r20","unstructured":"U.S. Food and Drug Administration. Design considerations for pivotal clinical investigations for medical devices. November 7, 2013. Accessed March 13, 2025. https:\/\/www.fda.gov\/media\/87363\/download."},{"key":"ioi250036r29","unstructured":"Li? H, Xu? Y, Yan? X. Statistical considerations for studies with a performance goal. JSM 2017 \u2013 Section on Medical Devices and Diagnostics. Accessed December 9, 2024. https:\/\/ww2.amstat.org\/meetings\/proceedings\/2017\/data\/assets\/pdf\/593825.pdf."},{"key":"ioi250036r30","unstructured":"U.S. Food and Drug Administration. Post-approval studies database. October 28, 2024. Accessed December 9, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma_pas.cfm."},{"key":"ioi250036r31","unstructured":"U.S. Food and Drug Administration. 522 postmarket surveillance studies database. October 28, 2024. Accessed December 9, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pss.cfm?s=t."},{"key":"ioi250036r32","unstructured":"U.S. Food and Drug Administration. Medical device recalls. November 1, 2024. Accessed December 9, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfres\/res.cfm."},{"key":"ioi250036r33","unstructured":"U.S. Food and Drug Administration. Symplicity Spyral\u2122 Renal Denervation System, P220026. November 17, 2023. Accessed December 9, 2024. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf22\/P220026B.pdf."},{"key":"ioi250036r34","unstructured":"U.S. Food and Drug Administration. Medtronic recalls Harmony delivery catheter, part of transcatheter pulmonary valve (TPV) system, for risk of capsule break during use. April 26, 2022. Accessed December 9, 2024. https:\/\/www.fda.gov\/medical-devices\/medical-device-recalls\/medtronic-recalls-harmony-delivery-catheter-part-transcatheter-pulmonary-valve-tpv-system-risk"},{"key":"ioi250036r35","unstructured":"U.S. Food and Drug Administration. Class 1 device recall Harmony delivery catheter system. December 2, 2024. Accessed December 9, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfRES\/res.cfm?id=192430."},{"key":"ioi250036r36","unstructured":"U.S. Food and Drug Administration. 510(k) premarket notification. December 2, 2024. Accessed December 9, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm."},{"key":"ioi250036r37","unstructured":"U.S. Food and Drug Administration. Premarket approval. December 2, 2024. Accessed December 9, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm."},{"key":"ioi250036r39","unstructured":"U.S. Food and Drug Administration. The 510(k) program: evaluating substantial equivalence in premarket notifications. July 28, 2014. Accessed December 9, 2024. https:\/\/www.fda.gov\/media\/82395\/download"},{"key":"ioi250036r41","unstructured":"U.S. Food and Drug Administration. Report to Congress: breakthrough devices program. 2018. Accessed December 9, 2024. https:\/\/www.fda.gov\/media\/124747\/download."},{"key":"ioi250036r46","unstructured":"U.S. Food and Drug Administration. CDER breakthrough therapy designations withdrawn after granting or rescinded by fiscal year. December 31, 2023. Accessed December 9, 2024. https:\/\/www.fda.gov\/media\/95269\/download."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2835682\/jamainternal_kadakia_2025_oi_250036_1757539054.15353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T15:01:06Z","timestamp":1757948466000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2835682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.2235","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}